First-line ICIs in renal cell carcinoma

被引：3
作者：
Fiorentino, Vincenzo [1 ,5 ]
Tralongo, Pietro [2 ]
Larocca, Luigi Maria [3 ]
Pizzimenti, Cristina [4 ]
Martini, Maurizio [1 ]
Pierconti, Francesco [2 ]
机构：
[1] Univ Messina, Dept Human Pathol Adult & Dev Age Gaetano Barresi, Pathol Sect, Messina, Italy
[2] Fdn Policlin Univ Agostino Gemelli IRCCS, Dept Woman & Childs Hlth & Publ Hlth Sci, Pathol Unit, Rome, Italy
[3] Int Med Univ Rome, Unicamillus, Rome, Italy
[4] Univ Messina, Dept Biomed & Dent Sci & Morphofunct Imaging, Translat Mol Med & Surg, Messina, Italy
[5] Univ Messina, Azienda Univ Osped G Martino, Via Consolare Valeria 1, I-90125 Messina, Italy
来源：
HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2023年 / 19卷 / 02期
关键词：
Immune checkpoint inhibition; INTERFERON-ALPHA; THERAPY; CANCER; EVEROLIMUS; INTERLEUKIN-2; PEMBROLIZUMAB; MONOTHERAPY; SUNITINIB; NIVOLUMAB; TRIAL;
D O I：
10.1080/21645515.2023.2225386
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Treatment of metastatic renal cell carcinoma (mRCC) has radically changed, switching from interferon alfa (IFN-& alpha;) and high-dose interleukin-2 (HD IL-2) to new targeted therapies directed against tumoral neoangiogenesis, the mammalian target of the rapamycin (mTOR) pathway and immune checkpoints. Of note, the inhibition of immune checkpoints restores antitumor immune response, therefore promoting immune-mediated elimination of neoplastic cells. The best example of this targeted treatment is represented by PD-1/PD-L1 inhibition that has become the standard of care in mRCC treatment and has improved mRCC patients' prognoses after failure of other targeted therapies. In this manuscript, we review the main therapeutic protocols adopted for mRCC, based on the use of immune checkpoint inhibitors (ICIs) alone or combined with other drugs.
引用
收藏
页数：7
相关论文
共 49 条
  • [1] Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial
    Albiges, Laurence
    Tannir, Nizar M.
    Burotto, Mauricio
    McDermott, David
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    George, Saby
    Kollmannsberger, Christian K.
    Gurney, Howard
    Grimm, Marc-Oliver
    Tomita, Yoshihiko
    Castellano, Daniel
    Rini, Brian, I
    Choueiri, Toni K.
    Saggi, Shruti Shally
    McHenry, M. Brent
    Motzer, Robert J.
    [J]. ESMO OPEN, 2020, 5 (06)
  • [2] Updated European Association of Urology Guidelines on Renal Cell Carcinoma: Nivolumab plus Cabozantinib Joins Immune Checkpoint Inhibition Combination Therapies for Treatment-naive Metastatic Clear-Cell Renal Cell Carcinoma
    Bedke, Jens
    Albiges, Laurence
    Capitanio, Umberto
    Giles, Rachel H.
    Hora, Milan
    Lam, Thomas B.
    Ljungberg, Borje
    Marconi, Lorenzo
    Klatte, Tobias
    Volpe, Alessandro
    Abu-Ghanem, Yasmin
    Dabestani, Saeed
    Fernandez-Pello, Sergio
    Hofmann, Fabian
    Kuusk, Teele
    Tahbaz, Rana
    Powles, Thomas
    Bex, Axel
    [J]. EUROPEAN UROLOGY, 2021, 79 (03) : 339 - 342
  • [3] Renal cancer
    Capitanio, Umberto
    Montorsi, Francesco
    [J]. LANCET, 2016, 387 (10021) : 894 - 906
  • [4] Patient-reported outcomes with first-line nivolumab plus cabozantinib versus sunitinib in patients with advanced renal cell carcinoma treated in CheckMate 9ER: an open-label, randomised, phase 3 trial
    Cella, David
    Motzer, Robert J.
    Suarez, Cristina
    Blum, Steven, I
    Ejzykowicz, Flavia
    Hamilton, Melissa
    Wallace, Joel F.
    Simsek, Burcin
    Zhang, Joshua
    Ivanescu, Cristina
    Apolo, Andrea B.
    Choueiri, Toni K.
    [J]. LANCET ONCOLOGY, 2022, 23 (02) : 292 - 303
  • [5] Patient-reported outcomes of patients with advanced renal cell carcinoma treated with nivolumab plus ipilimumab versus sunitinib (CheckMate 214): a randomised, phase 3 trial
    Cella, David
    Gruenwald, Viktor
    Escudier, Bernard
    Hammers, Hans J.
    George, Saby
    Nathan, Paul
    Grimm, Marc-Oliver
    Rini, Brian, I
    Doan, Justin
    Ivanescu, Cristina
    Paty, Jean
    Mekan, Sabeen
    Motzer, Robert J.
    [J]. LANCET ONCOLOGY, 2019, 20 (02) : 297 - 310
  • [6] Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
    Choueiri, T. K.
    Tomczak, P.
    Park, S. H.
    Venugopal, B.
    Ferguson, T.
    Chang, Y. -H.
    Hajek, J.
    Symeonides, S. N.
    Lee, J. L.
    Sarwar, N.
    Thiery-Vuillemin, A.
    Gross-Goupil, M.
    Mahave, M.
    Haas, N. B.
    Sawrycki, P.
    Gurney, H.
    Chevreau, C.
    Melichar, B.
    Kopyltsov, E.
    Alva, A.
    Burke, J. M.
    Doshi, G.
    Topart, D.
    Oudard, S.
    Hammers, H.
    Kitamura, H.
    Bedke, J.
    Perini, R. F.
    Zhang, P.
    Imai, K.
    Willemann-Rogerio, J.
    Quinn, D. I.
    Powles, T.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) : 683 - 694
  • [7] Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Escudier, B.
    Powles, T.
    Mainwaring, P. N.
    Rini, B. I.
    Donskov, F.
    Hammers, H.
    Hutson, T. E.
    Lee, J-L
    Peltola, K.
    Roth, B. J.
    Bjarnason, G. A.
    Geczi, L.
    Keam, B.
    Maroto, P.
    Heng, D. Y. C.
    Schmidinger, M.
    Kantoff, P. W.
    Borgman-Hagey, A.
    Hessel, C.
    Scheffold, C.
    Schwab, G. M.
    Tannir, N. M.
    Motzer, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (19) : 1814 - 1823
  • [8] Targeting the HIF2-VEGF axis in renal cell carcinoma
    Choueiri, Toni K.
    Kaelin, William G., Jr.
    [J]. NATURE MEDICINE, 2020, 26 (10) : 1519 - 1530
  • [9] Systemic Therapy for Metastatic Renal-Cell Carcinoma
    Choueiri, Toni K.
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2017, 376 (04) : 354 - 366
  • [10] Antiangiogenic therapy for advanced renal cell carcinoma: Management of treatment-related toxicities
    Cohen, Roger B.
    Oudard, Stephane
    [J]. INVESTIGATIONAL NEW DRUGS, 2012, 30 (05) : 2066 - 2079
12345